Ibere Pharmaceuticals
IBER
IBER was delisted on the 1st of March, 2023.
47 hedge funds and large institutions have $99.8M invested in Ibere Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 3 closing their positions.
367% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 3
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
40% more capital invested
Capital invested by funds: $71.4M → $99.8M (+$28.3M)
24% more funds holding
Funds holding: 38 → 47 (+9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Brown Advisory
Baltimore,
Maryland
|
+$26.5M |
| 2 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$3.27M |
| 3 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$2.43M |
| 4 |
D.E. Shaw & Co
New York
|
+$2.36M |
| 5 |
GCL
Glazer Capital LLC
New York
|
+$1.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
-$745K |
| 2 |
AM
Ampfield Management
New York
|
-$432K |
| 3 |
PCM
Prelude Capital Management
New York
|
-$35.3K |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$29K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$49 |
IBER Hedge Fund Activity: Q4 2021 in Review
47 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Ibere Pharmaceuticals (IBER) for Q4 2021, worth a combined $99.8M — up 40% from $71.4M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new IBER positions and 3 closed out — a net gain of 11 holders — while 8 added to existing stakes and 2 trimmed.
The largest buyer was Brown Advisory, opening a new position worth an estimated $26.5M. The largest seller was AQR Arbitrage, exiting entirely with an estimated $745K sold.
- 47 institutional investors held Ibere Pharmaceuticals (IBER) as of Q4 2021, up from 38 in Q3 2021.
- Funds reported $99.8M of Ibere Pharmaceuticals stock for Q4 2021, up 40% quarter-over-quarter.
- 14 funds opened new Ibere Pharmaceuticals positions in Q4 2021 and 3 closed out, a net change of +11 holders.
- The largest Ibere Pharmaceuticals buyer in Q4 2021 was Brown Advisory, an estimated $26.5M added.
- The largest Ibere Pharmaceuticals seller in Q4 2021 was AQR Arbitrage, an estimated $745K sold.
Based on aggregated 13F filings for Q4 2021.